MRNA vs SNPS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

MRNA

36.3
AI Score
VS
MRNA Wins

SNPS

27.0
AI Score

Investment Advisor Scores

MRNA

36score
Recommendation
SELL

SNPS

27score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA SNPS Winner
Revenue 534.00M 7.16B SNPS
Net Income -2.13B 627.86M SNPS
Net Margin -397.9% 8.8% SNPS
Operating Income -2.20B 680.96M SNPS
ROE -31.4% 2.0% SNPS
ROA -19.4% 1.3% SNPS
Total Assets 10.96B 47.73B SNPS
Cash 1.72B 3.61B SNPS
Debt/Equity 0.09 0.32 MRNA
Current Ratio 2.29 1.34 MRNA
Free Cash Flow -1.25B 2.14B SNPS

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% SNPS 1M: +28.2% · 3M: +13.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

SNPS

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.1% over 20 days), RSI 75

RSI (14): 74.9 · Price: $502.67

Fundamentals Snapshot

Metric MRNA SNPS
Market Cap — —
Forward P/E -41.0 27.1
Trailing P/E — 86.4
Revenue (TTM) — —
Revenue Growth 0.0% 0.4%
Gross Margin -0.7% 0.8%
Operating Margin -5.6% 0.1%
EPS -7.36 5.85
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.